JP2012524794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524794A5 JP2012524794A5 JP2012507341A JP2012507341A JP2012524794A5 JP 2012524794 A5 JP2012524794 A5 JP 2012524794A5 JP 2012507341 A JP2012507341 A JP 2012507341A JP 2012507341 A JP2012507341 A JP 2012507341A JP 2012524794 A5 JP2012524794 A5 JP 2012524794A5
- Authority
- JP
- Japan
- Prior art keywords
- quinazolin
- dimethoxy
- ethoxy
- dimethylphenyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 18
- -1 2-hydroxy-2-methylpropoxy, 2-hydroxyethoxy, methoxy, benzyloxyethoxy, 2,3-dihydroxypropoxy, aminocarbonylethoxy, methylaminocarbonylethoxy Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- MDOGCKRWWGCWCZ-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-(2-methoxyethoxy)-3H-quinazolin-4-one Chemical compound C=1C(OCCOC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(O)C(C)=C1 MDOGCKRWWGCWCZ-UHFFFAOYSA-N 0.000 claims 2
- HSIQEDUCBAIUCD-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-(2-phenylmethoxyethoxy)-3H-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C(C)C(O)=C(C)C=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CC=C1 HSIQEDUCBAIUCD-UHFFFAOYSA-N 0.000 claims 2
- ZBVMRQYXKHKMCA-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-[2-(pyridin-3-ylmethoxy)ethoxy]-3H-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C(C)C(O)=C(C)C=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CN=C1 ZBVMRQYXKHKMCA-UHFFFAOYSA-N 0.000 claims 2
- GGYCKROERKJIPH-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-6-(pyridin-2-ylamino)-3H-quinazolin-4-one Chemical compound CC1=C(O)C(C)=CC(C=2NC(=O)C3=CC(NC=4N=CC=CC=4)=CC=C3N=2)=C1 GGYCKROERKJIPH-UHFFFAOYSA-N 0.000 claims 2
- SRTWCIMCOKZRSD-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-6-(pyridin-4-ylamino)-3H-quinazolin-4-one Chemical compound CC1=C(O)C(C)=CC(C=2NC(=O)C3=CC(NC=4C=CN=CC=4)=CC=C3N=2)=C1 SRTWCIMCOKZRSD-UHFFFAOYSA-N 0.000 claims 2
- RHYDBUQWKLDSSH-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-6-[(4-methylpiperazin-1-yl)methyl]-3H-quinazolin-4-one Chemical compound C1CN(C)CCN1CC1=CC=C(N=C(NC2=O)C=3C=C(C)C(O)=C(C)C=3)C2=C1 RHYDBUQWKLDSSH-UHFFFAOYSA-N 0.000 claims 2
- APZNQSZDPRARPQ-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-5-(2-methoxyethoxy)-3H-quinazolin-4-one Chemical compound N1C(=O)C=2C(OCCOC)=CC(OC)=CC=2N=C1C1=CC(C)=C(O)C(C)=C1 APZNQSZDPRARPQ-UHFFFAOYSA-N 0.000 claims 2
- LKVSVQSRTKWFIL-UHFFFAOYSA-N 2-[2-(2-hydroxyethyl)-1h-indol-6-yl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=C2C=C(CCO)NC2=CC(C2=NC=3C(C(N2)=O)=C(OC)C=C(C=3)OC)=C1 LKVSVQSRTKWFIL-UHFFFAOYSA-N 0.000 claims 2
- PNFCSROGAPWESA-UHFFFAOYSA-N 2-[2-(hydroxymethyl)-1-benzofuran-5-yl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=C2OC(CO)=CC2=CC(C2=NC=3C(C(N2)=O)=C(OC)C=C(C=3)OC)=C1 PNFCSROGAPWESA-UHFFFAOYSA-N 0.000 claims 2
- BYWNULLIYPUOEP-UHFFFAOYSA-N 2-[2-(hydroxymethyl)-1-benzofuran-5-yl]-5-methoxy-7-(2-phenylmethoxyethoxy)-1h-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C4C=C(CO)OC4=CC=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CC=C1 BYWNULLIYPUOEP-UHFFFAOYSA-N 0.000 claims 2
- WALLOGAYHQWBIU-UHFFFAOYSA-N 2-[3,5-dimethyl-4-(2-phenylmethoxyethoxy)phenyl]-5,7-dimethoxy-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCOCC1=CC=CC=C1 WALLOGAYHQWBIU-UHFFFAOYSA-N 0.000 claims 2
- GUXJETKNLPSMFR-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(1,2-oxazol-3-ylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC=1C=CON=1 GUXJETKNLPSMFR-UHFFFAOYSA-N 0.000 claims 2
- PYLDFPVGGNHJSO-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(2,2,2-trifluoroethylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNCC(F)(F)F)C(C)=C1 PYLDFPVGGNHJSO-UHFFFAOYSA-N 0.000 claims 2
- JHHFAFANAXHNSU-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(methylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=C(C)C(OCCNC)=C(C)C=C1C1=NC2=CC(OC)=CC(OC)=C2C(=O)N1 JHHFAFANAXHNSU-UHFFFAOYSA-N 0.000 claims 2
- ZXCSEHMIVFVIHL-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(propan-2-ylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(C)C)C(C)=C1 ZXCSEHMIVFVIHL-UHFFFAOYSA-N 0.000 claims 2
- SULXIQQOIHSELL-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(pyrimidin-2-ylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC1=NC=CC=N1 SULXIQQOIHSELL-UHFFFAOYSA-N 0.000 claims 2
- IPZVRQMTFBFZMB-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-[(3-methyl-1,2,4-oxadiazol-5-yl)amino]ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC1=NC(C)=NO1 IPZVRQMTFBFZMB-UHFFFAOYSA-N 0.000 claims 2
- NWUMWUJCWZEQPR-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-[(5-methyl-1,2-oxazol-3-yl)amino]ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC=1C=C(C)ON=1 NWUMWUJCWZEQPR-UHFFFAOYSA-N 0.000 claims 2
- FYRBPTYMWCKKMI-UHFFFAOYSA-N 2-[4-(2,3-dihydroxypropoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCC(O)CO)C(C)=C1 FYRBPTYMWCKKMI-UHFFFAOYSA-N 0.000 claims 2
- IEFZYZBRJHLPQL-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-di(propan-2-yloxy)-1h-quinazolin-4-one Chemical compound C=1C(OC(C)C)=CC(OC(C)C)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 IEFZYZBRJHLPQL-UHFFFAOYSA-N 0.000 claims 2
- KAJOGFKWTONJNI-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-(morpholin-4-ylmethyl)-1h-quinazolin-4-one Chemical compound COC1=CC=2N=C(C=3C=C(C)C(OCCO)=C(C)C=3)NC(=O)C=2C(OC)=C1CN1CCOCC1 KAJOGFKWTONJNI-UHFFFAOYSA-N 0.000 claims 2
- LGPBXJVSEXVOLI-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethyl-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound N=1C(C)=CC(C)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 LGPBXJVSEXVOLI-UHFFFAOYSA-N 0.000 claims 2
- ZSNMJTCQIWYPEJ-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5-methoxy-7-(2-phenylmethoxyethoxy)-1h-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C(C)C(OCCO)=C(C)C=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CC=C1 ZSNMJTCQIWYPEJ-UHFFFAOYSA-N 0.000 claims 2
- XXHXTYXZQCOHLN-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-(morpholin-4-ylmethyl)-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC(CN4CCOCC4)=CC=C3N=2)=C1 XXHXTYXZQCOHLN-UHFFFAOYSA-N 0.000 claims 2
- DSFBHHRWCDCSHI-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-[(4-methylpiperazin-1-yl)methyl]-1h-quinazolin-4-one Chemical compound C1CN(C)CCN1CC1=CC=C(N=C(NC2=O)C=3C=C(C)C(OCCO)=C(C)C=3)C2=C1 DSFBHHRWCDCSHI-UHFFFAOYSA-N 0.000 claims 2
- YURGJGIKUMNQAG-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-morpholin-4-yl-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC(=CC=C3N=2)N2CCOCC2)=C1 YURGJGIKUMNQAG-UHFFFAOYSA-N 0.000 claims 2
- IQHGJLJMQNOOOM-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-7-methoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 IQHGJLJMQNOOOM-UHFFFAOYSA-N 0.000 claims 2
- BUTMYQZRONUNRA-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-8-methoxy-1h-quinazolin-4-one Chemical compound COC1=CC=CC(C(N2)=O)=C1N=C2C1=CC(C)=C(OCCO)C(C)=C1 BUTMYQZRONUNRA-UHFFFAOYSA-N 0.000 claims 2
- FPEWRFDXDFCNDC-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)naphthalen-1-yl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=CC=C2C(C3=NC=4C(C(N3)=O)=C(OC)C=C(C=4)OC)=CC=C(OCCO)C2=C1 FPEWRFDXDFCNDC-UHFFFAOYSA-N 0.000 claims 2
- WBTCFZCMHRLXQO-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCO)C=C1 WBTCFZCMHRLXQO-UHFFFAOYSA-N 0.000 claims 2
- HUOQPMXIZKHHSW-UHFFFAOYSA-N 2-[4-(3-hydroxypropyl)-3,5-dimethoxyphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(OC)=C(CCCO)C(OC)=C1 HUOQPMXIZKHHSW-UHFFFAOYSA-N 0.000 claims 2
- NHSUSPHYOQXLKI-UHFFFAOYSA-N 2-[4-(3-hydroxypropyl)-3-methoxyphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(CCCO)C(OC)=C1 NHSUSPHYOQXLKI-UHFFFAOYSA-N 0.000 claims 2
- PNJZRVOXBUCTOW-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]-n-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)COC1=C(C)C=C(C=2NC(=O)C3=C(OC)C=C(OC)C=C3N=2)C=C1C PNJZRVOXBUCTOW-UHFFFAOYSA-N 0.000 claims 2
- CNLOLXKDVFTTLW-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]-n-methylacetamide Chemical compound C1=C(C)C(OCC(=O)NC)=C(C)C=C1C1=NC2=CC(OC)=CC(OC)=C2C(=O)N1 CNLOLXKDVFTTLW-UHFFFAOYSA-N 0.000 claims 2
- YTLOXNQXTWFAJB-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethylcyanamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC#N)C(C)=C1 YTLOXNQXTWFAJB-UHFFFAOYSA-N 0.000 claims 2
- ZLYCVBKVYCOXGT-UHFFFAOYSA-N 2-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCN(C)C)C(C)=C1 ZLYCVBKVYCOXGT-UHFFFAOYSA-N 0.000 claims 2
- IHTUFOIGRIKCEF-UHFFFAOYSA-N 2-[4-[2-[(4,6-dimethoxypyrimidin-2-yl)amino]ethoxy]-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC1=NC(OC)=CC(OC)=N1 IHTUFOIGRIKCEF-UHFFFAOYSA-N 0.000 claims 2
- JJBNVQFJGXYJLO-UHFFFAOYSA-N 5,7-difluoro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=C(F)C=C(F)C=C3N=2)=C1 JJBNVQFJGXYJLO-UHFFFAOYSA-N 0.000 claims 2
- GTUAWCNRLUGFCM-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-methyl-4-[2-[(5-phenyl-1h-1,2,4-triazol-3-yl)amino]ethoxy]phenyl]-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC=C1OCCNC(N1)=NN=C1C1=CC=CC=C1 GTUAWCNRLUGFCM-UHFFFAOYSA-N 0.000 claims 2
- YZJRQXLNLOJQBC-UHFFFAOYSA-N 5-[2-(dimethylamino)ethoxy]-2-(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3H-quinazolin-4-one Chemical compound C=1C(OC)=CC(OCCN(C)C)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(O)C(C)=C1 YZJRQXLNLOJQBC-UHFFFAOYSA-N 0.000 claims 2
- HGUHCPZTHPCUIQ-UHFFFAOYSA-N 5-chloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=C(Cl)C=CC=C3N=2)=C1 HGUHCPZTHPCUIQ-UHFFFAOYSA-N 0.000 claims 2
- JMCGLFZNIJLKPI-UHFFFAOYSA-N 7-(2-aminoethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-3H-quinazolin-4-one Chemical compound N1C(=O)C=2C(OC)=CC(OCCN)=CC=2N=C1C1=CC(C)=C(O)C(C)=C1 JMCGLFZNIJLKPI-UHFFFAOYSA-N 0.000 claims 2
- PWDSZMUIVXNRGI-UHFFFAOYSA-N 7-[2-(dimethylamino)ethoxy]-2-(4-hydroxy-3,5-dimethylphenyl)-3H-quinazolin-4-one Chemical compound C=1C(OCCN(C)C)=CC=C(C(N2)=O)C=1N=C2C1=CC(C)=C(O)C(C)=C1 PWDSZMUIVXNRGI-UHFFFAOYSA-N 0.000 claims 2
- ISDAEGUKMVOWHV-UHFFFAOYSA-N 7-chloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC=C(Cl)C=C3N=2)=C1 ISDAEGUKMVOWHV-UHFFFAOYSA-N 0.000 claims 2
- XYXAPLAQQRDOOI-UHFFFAOYSA-N 8-chloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC=CC(Cl)=C3N=2)=C1 XYXAPLAQQRDOOI-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- GITDYDRJUITKMH-UHFFFAOYSA-N N-[[2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3H-quinazolin-6-yl]methyl]methanesulfonamide Chemical compound CC1=C(O)C(C)=CC(C=2NC(=O)C3=CC(CNS(C)(=O)=O)=CC=C3N=2)=C1 GITDYDRJUITKMH-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- XAQKZGVWOHQWGE-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-n-methylacetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCN(C)C(C)=O)C(C)=C1 XAQKZGVWOHQWGE-UHFFFAOYSA-N 0.000 claims 2
- PTBASXYYZNQXGP-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-n-methylformamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCN(C)C=O)C(C)=C1 PTBASXYYZNQXGP-UHFFFAOYSA-N 0.000 claims 2
- MRPBLCPVJYSEHZ-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]formamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC=O)C(C)=C1 MRPBLCPVJYSEHZ-UHFFFAOYSA-N 0.000 claims 2
- JXYULCWHTVYMQB-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]propane-2-sulfonamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNS(=O)(=O)C(C)C)C(C)=C1 JXYULCWHTVYMQB-UHFFFAOYSA-N 0.000 claims 2
- KJJJKBFEBDERSM-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2-methylphenoxy]ethyl]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCNC(C)=O)C(C)=C1 KJJJKBFEBDERSM-UHFFFAOYSA-N 0.000 claims 2
- JTJFFTKRYUMYHA-UHFFFAOYSA-N n-[2-[4-(6,8-dimethoxy-1-oxo-2h-isoquinolin-3-yl)-2,6-dimethylphenoxy]ethyl]formamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1C=C2C1=CC(C)=C(OCCNC=O)C(C)=C1 JTJFFTKRYUMYHA-UHFFFAOYSA-N 0.000 claims 2
- PLSBTFRYIVHGQQ-UHFFFAOYSA-N n-[[4-(5,7-dimethoxy-4-oxo-1h-pyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethylphenyl]methyl]acetamide Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(CNC(C)=O)C(C)=C1 PLSBTFRYIVHGQQ-UHFFFAOYSA-N 0.000 claims 2
- AYYRYDJWOZCCDK-UHFFFAOYSA-N n-[[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenyl]methyl]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(CNC(C)=O)C(C)=C1 AYYRYDJWOZCCDK-UHFFFAOYSA-N 0.000 claims 2
- SCJYDQMKIATBOJ-UHFFFAOYSA-N n-benzyl-2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCC(=O)NCC1=CC=CC=C1 SCJYDQMKIATBOJ-UHFFFAOYSA-N 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- BHAJCEWFKZUIKQ-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 BHAJCEWFKZUIKQ-UHFFFAOYSA-N 0.000 claims 1
- PQVHQVOOKNUBMB-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5-methoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C(OC)=CC=CC=2N=C1C1=CC(C)=C(OCCO)C(C)=C1 PQVHQVOOKNUBMB-UHFFFAOYSA-N 0.000 claims 1
- RJKSYSAMNAUDLG-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1C1=CC(C)=C(OCCO)C(C)=C1 RJKSYSAMNAUDLG-UHFFFAOYSA-N 0.000 claims 1
- NSYBXWYSRKNEDE-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-methoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C2=CC(OC)=CC=C2N=C1C1=CC(C)=C(OCCO)C(C)=C1 NSYBXWYSRKNEDE-UHFFFAOYSA-N 0.000 claims 1
- SJASEOKEWBPIRK-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3-methylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCO)C(C)=C1 SJASEOKEWBPIRK-UHFFFAOYSA-N 0.000 claims 1
- XTOOVRVEMJAQFN-UHFFFAOYSA-N 2-[4-(4-hydroxybutoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCCCO)C(C)=C1 XTOOVRVEMJAQFN-UHFFFAOYSA-N 0.000 claims 1
- GIKJRBPNAUVPAL-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCC(N)=O)C(C)=C1 GIKJRBPNAUVPAL-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- LPPHEORVQUBKAI-UHFFFAOYSA-N 3-[4-(2-hydroxy-2-methylpropoxy)-3,5-dimethylphenyl]-6,8-dimethoxy-2h-isoquinolin-1-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1C=C2C1=CC(C)=C(OCC(C)(C)O)C(C)=C1 LPPHEORVQUBKAI-UHFFFAOYSA-N 0.000 claims 1
- LFUOKUQHDNOIFT-UHFFFAOYSA-N 5,7-dichloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=C(Cl)C=C(Cl)C=C3N=2)=C1 LFUOKUQHDNOIFT-UHFFFAOYSA-N 0.000 claims 1
- YOHOTAMJRCWPER-UHFFFAOYSA-N 5,7-dimethoxy-2-(4-methoxy-3,5-dimethylphenyl)-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OC)C(C)=C1 YOHOTAMJRCWPER-UHFFFAOYSA-N 0.000 claims 1
- COODZPZBQVVMAI-UHFFFAOYSA-N 5,7-dimethoxy-2-(4-methoxyphenyl)-1h-quinazolin-4-one Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC(OC)=CC(OC)=C2C(=O)N1 COODZPZBQVVMAI-UHFFFAOYSA-N 0.000 claims 1
- AOJDYFWLCVYXPC-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-3-(morpholin-4-ylmethyl)phenyl]-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=1)=CC=C(OC)C=1CN1CCOCC1 AOJDYFWLCVYXPC-UHFFFAOYSA-N 0.000 claims 1
- JWSHPKBSBZOEHQ-UHFFFAOYSA-N CC(=O)NCCOC(C(=O)N(C)CCO)OCCN(C)C Chemical compound CC(=O)NCCOC(C(=O)N(C)CCO)OCCN(C)C JWSHPKBSBZOEHQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- RHHHGOZXDBLBFM-UHFFFAOYSA-N n-[2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-4-oxo-1h-quinazolin-6-yl]acetamide Chemical compound N1C(=O)C2=CC(NC(=O)C)=CC=C2N=C1C1=CC(C)=C(OCCO)C(C)=C1 RHHHGOZXDBLBFM-UHFFFAOYSA-N 0.000 claims 1
- QFZHJVFIABNVNU-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-pyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethylphenoxy]ethyl]acetamide Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(C)=O)C(C)=C1 QFZHJVFIABNVNU-UHFFFAOYSA-N 0.000 claims 1
- ITRVWWNOGMNDNQ-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-2-methylpropanamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(=O)C(C)C)C(C)=C1 ITRVWWNOGMNDNQ-UHFFFAOYSA-N 0.000 claims 1
- PFHMVLYQAPTQRQ-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCCOC1=C(C)C=C(C=2NC(=O)C3=C(OC)C=C(OC)C=C3N=2)C=C1C PFHMVLYQAPTQRQ-UHFFFAOYSA-N 0.000 claims 1
- JPXFKHCUTSMVGP-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(C)=O)C(C)=C1 JPXFKHCUTSMVGP-UHFFFAOYSA-N 0.000 claims 1
- PIRVGPWBOGNYAH-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]methanesulfonamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNS(C)(=O)=O)C(C)=C1 PIRVGPWBOGNYAH-UHFFFAOYSA-N 0.000 claims 1
- YVVMUNNSVSVEEV-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2-methylphenoxy]ethyl]-2-methylpropanamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCNC(=O)C(C)C)C(C)=C1 YVVMUNNSVSVEEV-UHFFFAOYSA-N 0.000 claims 1
- STAOOJVYTOKHDK-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2-methylphenoxy]ethyl]methanesulfonamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCNS(C)(=O)=O)C(C)=C1 STAOOJVYTOKHDK-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17162009P | 2009-04-22 | 2009-04-22 | |
| US61/171,620 | 2009-04-22 | ||
| PCT/US2010/031870 WO2010123975A1 (en) | 2009-04-22 | 2010-04-21 | Novel anti-inflammatory agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524794A JP2012524794A (ja) | 2012-10-18 |
| JP2012524794A5 true JP2012524794A5 (https=) | 2013-06-13 |
| JP5813626B2 JP5813626B2 (ja) | 2015-11-17 |
Family
ID=42236704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507341A Expired - Fee Related JP5813626B2 (ja) | 2009-04-22 | 2010-04-21 | 新規抗炎症剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9757368B2 (https=) |
| EP (2) | EP3431086B1 (https=) |
| JP (1) | JP5813626B2 (https=) |
| KR (4) | KR20190091564A (https=) |
| CN (2) | CN107252429B (https=) |
| AU (1) | AU2010239266B2 (https=) |
| BR (1) | BRPI1014956B8 (https=) |
| CA (1) | CA2759241C (https=) |
| DK (1) | DK2421533T3 (https=) |
| ES (2) | ES2706651T3 (https=) |
| HR (1) | HRP20182200T1 (https=) |
| IL (2) | IL215799A (https=) |
| LT (1) | LT2421533T (https=) |
| MX (2) | MX374414B (https=) |
| NZ (1) | NZ596117A (https=) |
| PL (1) | PL2421533T3 (https=) |
| PT (1) | PT2421533T (https=) |
| SI (1) | SI2421533T1 (https=) |
| TR (1) | TR201818390T4 (https=) |
| WO (1) | WO2010123975A1 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2617213C (en) * | 2005-07-29 | 2014-01-28 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| WO2008092231A1 (en) | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| JP2012505927A (ja) * | 2008-10-22 | 2012-03-08 | エフ．ホフマン−ラ ロシュ アーゲー | Ｊｎｋのピリミジニルピリドン阻害剤 |
| AU2010204106B2 (en) | 2009-01-08 | 2014-05-08 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| NZ755378A (en) | 2009-03-18 | 2022-07-29 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| ITMI20100984A1 (it) * | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| US8710064B2 (en) * | 2011-10-20 | 2014-04-29 | China Medical University | 2-aryl-4-quinazolinones and their pharmaceutical compositions |
| RU2640115C2 (ru) | 2011-11-01 | 2017-12-26 | Ресверлоджикс Корп. | Фармацевтические композиции замещенных хиназолинонов |
| CA2865511A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US20130281398A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281397A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281399A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| RS56846B1 (sr) | 2012-10-15 | 2018-04-30 | Resverlogix Corp | Jedinjenja korisna za sintezu jedinjenja benzamida |
| TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2014129796A1 (en) | 2013-02-20 | 2014-08-28 | Lg Life Sciences Ltd. | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CN103601675B (zh) * | 2013-10-08 | 2015-10-28 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| HK1246273B (en) | 2014-12-01 | 2019-12-06 | 恒翼生物医药(上海)股份有限公司 | Substituted pyridines as bromodomain inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3230277B1 (en) | 2014-12-11 | 2019-09-18 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
| JO3789B1 (ar) * | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
| WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
| US10456405B2 (en) | 2015-09-07 | 2019-10-29 | Zhejiang Huahai Pharmaceutical Co., Ltd | Nitric oxide-releasing prodrug molecule of substituted quinazolines |
| EP3416969B1 (en) | 2016-02-15 | 2021-05-05 | The Regents of The University of Michigan | Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| WO2017176958A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| MX384905B (es) | 2016-04-12 | 2025-03-14 | Univ Michigan Regents | Degradadores de proteínas de bromodominio y dominioextraterminal (bet). |
| EP3512855B1 (en) | 2016-09-13 | 2022-07-27 | The Regents of the University of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| CA3036841A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
| WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| CN108069954B (zh) * | 2017-03-03 | 2018-11-23 | 上海华汇拓医药科技有限公司 | 含no供体的喹唑啉酮化合物 |
| CA3104810A1 (en) * | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | Enhancing gaba's ability to modulate immune responses |
| WO2019055444A1 (en) | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS |
| CN108484510B (zh) * | 2018-05-18 | 2020-05-05 | 东南大学 | 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用 |
| AU2020377539B2 (en) | 2019-11-05 | 2025-05-29 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| CN115710202B (zh) * | 2021-08-23 | 2024-05-03 | 江西同和药业股份有限公司 | 一种阿帕他酮关键中间体的制备方法及其应用 |
| CN113845484B (zh) * | 2021-09-07 | 2023-06-30 | 四川大学 | 喹唑啉类小分子抑制剂及其在抗肿瘤药物中的应用 |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| KR20240045472A (ko) * | 2022-09-30 | 2024-04-08 | 주식회사 베노바이오 | 퀴나졸린염 화합물을 포함하는 관절염 치료용 조성물 및 이의 제조 방법 |
Family Cites Families (234)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2065593A (en) | 1936-12-29 | Water-soluble diazoimino com | ||
| FR472489A (fr) | 1914-02-20 | 1914-12-08 | Stas Motor Ges M B H | Bague de garniture métallique pour pistons |
| US2065900A (en) | 1935-03-23 | 1936-12-29 | Gen Aniline Works Inc | Dihydroxystilbene-dicarboxylic acid and a process of preparing it |
| FR803619A (fr) | 1935-03-23 | 1936-10-05 | Ig Farbenindustrie Ag | Acide du type dihydroxystilbène-dicarboxylique et son procédé de préparation |
| DE637259C (de) | 1935-03-24 | 1936-10-27 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung einer Dioxystilbendicarbonsaeure |
| FR803201A (fr) | 1935-07-08 | 1936-09-25 | Ste Ind Chim Bale | Préparation d'acides sulfoniques |
| US2071329A (en) | 1935-08-22 | 1937-02-23 | Solvay Process Co | Method of recovering phthalic anhydride |
| DE652772C (de) | 1935-11-07 | 1937-11-08 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von N-Dihydroazinen der Anthrachinonreihe |
| GB728767A (en) | 1951-10-12 | 1955-04-27 | Wander Ag Dr A | 2-substituted chromone compounds, and a method of making same |
| US3251837A (en) | 1962-09-14 | 1966-05-17 | Pfizer & Co C | Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides |
| GB1179019A (en) | 1967-05-23 | 1970-01-28 | Produits Chimique Soc Et | Polynicotinic Esters of Flavonoids |
| FR6928M (https=) | 1967-11-24 | 1969-05-05 | ||
| US3600394A (en) | 1968-05-17 | 1971-08-17 | Searle & Co | 2-aminoalkyl-3-arylisocarbostyrils |
| US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| DE2349024A1 (de) | 1973-09-26 | 1975-04-10 | Schering Ag | 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione |
| IT1050750B (it) | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
| US4159330A (en) | 1976-11-02 | 1979-06-26 | Carlo Erba S.P.A. | 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation |
| US5098903A (en) | 1980-03-07 | 1992-03-24 | Board Of Regents Of The University Of Oklahoma | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents |
| IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
| DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| EP0182213B1 (en) | 1984-11-08 | 1990-09-26 | Sumitomo Pharmaceuticals Company, Limited | Carbapenem compounds and production thereof |
| DE3515882A1 (de) | 1985-05-03 | 1986-11-06 | Dr. Karl Thomae Gmbh, 7950 Biberach | Arzneimittel, enthaltend pyridinone mit antithrombotischen wirkungen und verfahren zu ihrer herstellung |
| DE3532279A1 (de) | 1985-09-11 | 1987-03-12 | Bayer Ag | 1,4-benzoxathiin-derivate |
| DE3601417A1 (de) | 1986-01-20 | 1987-07-23 | Nattermann A & Cie | 2'-alkyl-(alkenyl-) substituierte quercetine |
| EP0258190B1 (de) | 1986-08-29 | 1991-11-27 | Ciba-Geigy Ag | Verfahren zur Herstellung von aromatischen Ether- und Thioetherverbindungen |
| EP0272455B1 (en) | 1986-11-24 | 1993-02-10 | Fujisawa Pharmaceutical Co., Ltd. | 3-Pyrrolidinylthio-1-azabicyclo [3.2.0] hept-2-ene-2-carboxylic acid compounds |
| GB8804058D0 (en) | 1988-02-22 | 1988-03-23 | Fujisawa Pharmaceutical Co | 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds |
| US4925838A (en) | 1988-03-18 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
| US4963544A (en) | 1988-05-23 | 1990-10-16 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
| GB8926981D0 (en) | 1988-12-23 | 1990-01-17 | Ici Plc | Heterocyclic derivatives |
| IE902465A1 (en) | 1989-07-07 | 1991-02-13 | Schering Corp | Pharmaceutically active compounds |
| FR2649612A1 (fr) | 1989-07-17 | 1991-01-18 | Rhone Poulenc Sante | Medicaments a base de derives de 1h-benzoxadiazine-4,1,2 nouveaux derives et leurs procedes de preparation |
| IE64358B1 (en) | 1989-07-18 | 1995-07-26 | Ici Plc | Diaryl ether heterocycles |
| GB9018134D0 (en) | 1989-09-29 | 1990-10-03 | Ici Plc | Heterocyclic derivatives |
| JP3180344B2 (ja) | 1990-06-05 | 2001-06-25 | 東レ株式会社 | インドール誘導体 |
| JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Ｄｎａおよびその用途 |
| IE913866A1 (en) | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
| GB9025832D0 (en) | 1990-11-28 | 1991-01-09 | Ashwell Geoffrey J | Novel films for nonlinear optical applications |
| US5126351A (en) | 1991-01-24 | 1992-06-30 | Glaxo Inc. | Antitumor compounds |
| MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| AU1746392A (en) | 1991-04-10 | 1992-11-17 | Octamer, Inc. | A method for inhibition of retroviral replication |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5124337A (en) | 1991-05-20 | 1992-06-23 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase |
| US5223506A (en) | 1991-06-04 | 1993-06-29 | Glaxo Inc. | Cyclic antitumor compounds |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| US5474994A (en) | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
| FR2689127B1 (fr) | 1992-03-31 | 1994-05-06 | Adir Cie | Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| US7655699B1 (en) * | 1992-04-22 | 2010-02-02 | Eisai Inc. | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
| DE4215588A1 (de) | 1992-05-12 | 1993-11-18 | Bayer Ag | Biphenylmethyl-substituierte Pyridone |
| DE4215587A1 (de) | 1992-05-12 | 1993-11-18 | Bayer Ag | Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone |
| GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| JPH0680656A (ja) | 1992-09-03 | 1994-03-22 | Mitsui Petrochem Ind Ltd | 光学活性エポキシドの製造方法 |
| AU5850894A (en) | 1992-12-23 | 1994-07-19 | Procept, Inc. | Novel agents for inhibition of hiv infectivity and use therefor |
| JPH0741442A (ja) | 1993-05-21 | 1995-02-10 | Sumitomo Chem Co Ltd | アセチレンアルコール誘導体およびその製造法 |
| JPH0761942A (ja) | 1993-06-17 | 1995-03-07 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
| JPH0725761A (ja) | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
| EP0709373B1 (en) | 1993-07-23 | 2001-10-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pyrrolidine derivative |
| US5707547A (en) | 1993-08-03 | 1998-01-13 | Sumitomo Chemical Company, Limited | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition |
| JPH07118241A (ja) | 1993-09-01 | 1995-05-09 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
| JPH07179380A (ja) | 1993-12-22 | 1995-07-18 | Sumitomo Chem Co Ltd | アルコール誘導体およびその製造法 |
| JPH07233109A (ja) | 1994-02-24 | 1995-09-05 | Sumitomo Chem Co Ltd | 光学活性なアルコール誘導体およびその製造法 |
| AU680736B2 (en) | 1994-02-25 | 1997-08-07 | Banyu Pharmaceutical Co., Ltd. | Carbapenem derivative |
| US5798344A (en) | 1994-03-08 | 1998-08-25 | Otsuka Pharmaceutical Factory, Inc. | Phosphonic ester derivatives of quinazolinones |
| JPH07247289A (ja) | 1994-03-11 | 1995-09-26 | Mitsui Petrochem Ind Ltd | クロメンオキシド類の製造方法 |
| FR2718329B1 (fr) | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
| US6048903A (en) | 1994-05-03 | 2000-04-11 | Robert Toppo | Treatment for blood cholesterol with trans-resveratrol |
| US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
| JP3702493B2 (ja) | 1994-08-12 | 2005-10-05 | 大正製薬株式会社 | キナゾリン−４（３ｈ）−オン誘導体 |
| HUT76853A (en) | 1994-11-14 | 1997-12-29 | Warner Lambert Co | 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same |
| IL115256A0 (en) | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5446071A (en) | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
| JP4140981B2 (ja) | 1994-12-26 | 2008-08-27 | 東菱薬品工業株式会社 | 再狭窄症及び動脈硬化症治療薬 |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| WO1996031206A2 (en) | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
| ES2180702T3 (es) | 1995-06-07 | 2003-02-16 | Lilly Co Eli | Tratamiento de patologias por la induccion del factor de transcripcion bef-1. |
| CN1090621C (zh) | 1995-08-30 | 2002-09-11 | 株式会社大冢制药厂 | 制备喹唑啉－4－酮衍生物的方法 |
| US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| AU4858596A (en) | 1995-09-15 | 1997-04-01 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
| KR19990067010A (ko) | 1995-10-23 | 1999-08-16 | 오스테오스크린, 인코포레이티드 | 골결핍 상태의 치료용 조성물 및 그 치료방법 |
| HU224225B1 (hu) | 1995-12-01 | 2005-06-28 | Sankyo Co. Ltd. | Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására |
| US5756736A (en) | 1996-01-26 | 1998-05-26 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
| US5763608A (en) | 1996-02-05 | 1998-06-09 | Hoechst Celanese Corporation | Process for preparing pyrimidine derivatives |
| US5739330A (en) | 1996-02-05 | 1998-04-14 | Hoechst Celanese Corporation | Process for preparing quinazolones |
| ES2161442T3 (es) | 1996-02-12 | 2001-12-01 | Univ Rutgers | Analogos de coralina como inhibidores de topoisomerasa. |
| HUP9904567A3 (en) | 1996-06-20 | 2001-10-29 | Univ Texas | Use of azo, thioalkyl, thiocarbonyl derivatives substituted by fused heterocycles and/or phenyl group for the preparation of pharmaceutical compositions stimulating bone growth |
| US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| KR100213895B1 (ko) | 1996-10-14 | 1999-08-02 | 박원훈 | 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물 |
| DE19651099A1 (de) | 1996-12-09 | 1998-06-10 | Consortium Elektrochem Ind | Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung |
| IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
| JPH10287678A (ja) | 1997-04-11 | 1998-10-27 | Kyowa Hakko Kogyo Co Ltd | ピラノアジン誘導体 |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| AU745790B2 (en) | 1997-05-13 | 2002-03-28 | Octamer, Inc. | Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors |
| US5908861A (en) | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
| CN100525766C (zh) | 1997-06-02 | 2009-08-12 | 詹森药业有限公司 | 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物 |
| IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| TW450964B (en) | 1997-08-29 | 2001-08-21 | Takeda Schering Plough Animal | Triazine derivatives, their production and use |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6239114B1 (en) | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| CN1124134C (zh) | 1997-10-28 | 2003-10-15 | 韩国科学技术研究院 | 柚苷和柚苷配基作为肝病的预防或治疗剂的应用 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| DE19756388A1 (de) | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
| JP2002500039A (ja) | 1998-01-08 | 2002-01-08 | アベンティス ファーマスーティカルズ プロダクツ インコーポレイテッド | 機能あるヒトリポタンパク質（ａ）を発現するトランスジェニックウサギ |
| US6414037B1 (en) | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| DK1074268T3 (da) | 1998-03-17 | 2008-04-28 | Chugai Pharmaceutical Co Ltd | IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme |
| US6022901A (en) | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
| ATE350060T1 (de) | 1998-08-24 | 2007-01-15 | Chugai Pharmaceutical Co Ltd | Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| KR20010079922A (ko) | 1998-09-24 | 2001-08-22 | 미우라 아키라 | 하이드록시플라본 유도체 |
| WO2000023075A1 (fr) | 1998-10-19 | 2000-04-27 | Eisai Co., Ltd. | Analgesiques |
| CN1327384A (zh) | 1998-10-20 | 2001-12-19 | 韩国科学技术研究院 | 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮 |
| AU2190700A (en) | 1998-12-17 | 2000-07-03 | Tularik Inc. | Tubulin-binding agents |
| US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| NZ513206A (en) | 1999-03-15 | 2004-02-27 | Abbott Lab | 6-O-substituted macrolides having antibacterial activity |
| US6969720B2 (en) | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
| US6054435A (en) | 1999-03-19 | 2000-04-25 | Abbott Laboratories | 6-O-substituted macrolides having antibacterial activity |
| NZ515086A (en) | 1999-04-28 | 2003-10-31 | Aventis Pharma Gmbh | Di-aryl acid derivatives as PPAR receptor ligands |
| US6835755B1 (en) | 1999-06-24 | 2004-12-28 | University Of Pretoria | Naphthoquinone derivatives and their use in the treatment and control of tuberculosis |
| DE19934799B4 (de) | 1999-07-28 | 2008-01-24 | Az Electronic Materials (Germany) Gmbh | Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten |
| JP2001131151A (ja) | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
| JP5278983B2 (ja) | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
| DE60043120D1 (de) | 1999-12-06 | 2009-11-19 | Welichem Biotech Inc | Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer |
| FR2804679B1 (fr) | 2000-02-07 | 2002-04-26 | Clariant France Sa | Nouveaux composes phenoliques derives des dialcoxyethanals, leur procede de preparation et leur application |
| EP1183224B1 (en) | 2000-02-17 | 2004-08-04 | Appleton Papers Inc. | Process for preparing alkoxy or arylmethoxy aroxyethanes |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| US6548694B2 (en) | 2000-05-23 | 2003-04-15 | Hoffman-La Roche Inc. | N-(4-carbamimidoyl-phenyl)-glycine derivatives |
| JP2001335476A (ja) | 2000-05-29 | 2001-12-04 | Shionogi & Co Ltd | 三環化合物の新規用途 |
| US6479499B1 (en) | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
| US20020025301A1 (en) | 2000-07-04 | 2002-02-28 | Sylke Haremza | Novel flavonoids and their use in cosmetic and dermatological preparations |
| US6541522B2 (en) | 2000-08-16 | 2003-04-01 | Insmed Incorporated | Methods of using compositions containing hypotriglyceridemically active stilbenoids |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| PL362546A1 (en) | 2000-10-05 | 2004-11-02 | Fujisawa Pharmaceutical Co, Ltd. | Benzamide compounds as apo b secretion inhibitors |
| MXPA03003024A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de sulfoxido y bis-sulfoxido y composiciones para el control de colesterol y usos relacionados. |
| AU2002211666A1 (en) | 2000-10-11 | 2002-04-22 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| IL154984A0 (en) | 2000-10-19 | 2003-10-31 | Merck & Co Inc | Estrogen receptor modulators |
| CN1285601C (zh) | 2000-11-30 | 2006-11-22 | 佳能株式会社 | 发光器件和显示器 |
| IL156315A0 (en) | 2000-12-07 | 2004-01-04 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| KR100472694B1 (ko) | 2000-12-30 | 2005-03-07 | 한국생명공학연구원 | 플라바논 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물 |
| JP2002249483A (ja) | 2001-02-21 | 2002-09-06 | Koei Chem Co Ltd | アリール置換複素環式化合物の製造法 |
| WO2002074307A1 (en) | 2001-03-16 | 2002-09-26 | Novogen Research Pty Ltd | Treatment of restenosis |
| WO2002087556A2 (en) | 2001-04-11 | 2002-11-07 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| JP2005504047A (ja) | 2001-08-13 | 2005-02-10 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | 紫外線吸収剤 |
| US20040248950A1 (en) | 2001-08-24 | 2004-12-09 | Natsuki Ishizuka | Apo ai expression accelerating agent |
| US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
| US20040235877A1 (en) | 2001-09-14 | 2004-11-25 | Natsuki Ishizuka | Novel use of tricyclic compound |
| US6835469B2 (en) | 2001-10-17 | 2004-12-28 | The University Of Southern California | Phosphorescent compounds and devices comprising the same |
| US7250512B2 (en) | 2001-11-07 | 2007-07-31 | E. I. Du Pont De Nemours And Company | Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds |
| US7166368B2 (en) | 2001-11-07 | 2007-01-23 | E. I. Du Pont De Nemours And Company | Electroluminescent platinum compounds and devices made with such compounds |
| US6541045B1 (en) | 2002-01-04 | 2003-04-01 | Nutraceutical Corporation | Herbal composition and method for combating inflammation |
| WO2003064399A1 (fr) | 2002-01-28 | 2003-08-07 | Ube Industries, Ltd. | Procede de production de derive de quinazolin-4-one |
| US20040127492A1 (en) | 2002-02-19 | 2004-07-01 | Pharmacia Corporation | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| NZ556545A (en) | 2002-03-22 | 2009-03-31 | Novartis Ag | Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003238157A1 (en) | 2002-06-18 | 2003-12-31 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| KR20040001144A (ko) | 2002-06-27 | 2004-01-07 | 김대경 | 신규한 적혈구 세포질형 포스포리파아제 에이 투 효소,그에 대한 항체, 이들의 용도 및 제조 방법 |
| US20050080021A1 (en) | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders |
| US20040033480A1 (en) | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
| US20050080024A1 (en) | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
| US20040087590A1 (en) | 2002-08-23 | 2004-05-06 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
| AU2003262946A1 (en) | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| EP1407774A1 (en) | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| WO2004032846A2 (en) | 2002-10-07 | 2004-04-22 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
| US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
| WO2004039795A2 (en) | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
| BR0316375A (pt) | 2002-11-18 | 2005-10-04 | Hoffmann La Roche | Diazinopirimidinas |
| KR100772297B1 (ko) | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
| ES2270154T3 (es) | 2002-12-13 | 2007-04-01 | F. Hoffmann-La Roche Ag | Derivados de 3h-quinazolin-4-ona. |
| ITRM20020629A1 (it) | 2002-12-19 | 2004-06-20 | Sigma Tau Ind Farmaceuti | Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante. |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換６，６−ヘテロ二環式誘導体 |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| WO2004072042A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivative and their use for modulation of lxr activity |
| WO2004092154A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| EP1610774A4 (en) | 2003-04-09 | 2008-07-16 | Exelixis Inc | TIE-2 MODULATORS AND METHODS OF USE |
| JP2004307440A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩 |
| ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| KR101205257B1 (ko) | 2003-06-06 | 2012-11-27 | 아렉시스 악티에볼라그 | 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의 융합된 헤테로사이클 화합물의 용도 |
| WO2004112710A2 (en) | 2003-06-17 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß |
| EP1637523A4 (en) | 2003-06-18 | 2009-01-07 | Ube Industries | PROCESS FOR PRODUCING A PYRIMIDIN-4-ONE COMPOUND |
| US20050043300A1 (en) | 2003-08-14 | 2005-02-24 | Pfizer Inc. | Piperazine derivatives |
| CN1925862A (zh) | 2003-10-10 | 2007-03-07 | 雷斯弗洛吉克斯公司 | 与egr－1增强子元件有关的疾病的治疗 |
| AU2004286277A1 (en) | 2003-10-28 | 2005-05-12 | Reddy Us Therapeutics, Inc. | Heterocyclic compounds and methods of making and using thereof |
| JP2007517071A (ja) | 2003-12-19 | 2007-06-28 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| CN1960977B (zh) | 2004-05-31 | 2010-07-21 | 万有制药株式会社 | 喹唑啉衍生物 |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006012577A2 (en) | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
| US20070218155A1 (en) | 2004-08-20 | 2007-09-20 | Kuhrts Eric H | Methods and compositions for treating dyslipidaemia |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| US20080152595A1 (en) | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| JP2008526734A (ja) | 2004-12-31 | 2008-07-24 | エスケー ケミカルズ カンパニー リミテッド | 糖尿及び肥満治療予防に有効なキナゾリン誘導体 |
| CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| CA2617213C (en) * | 2005-07-29 | 2014-01-28 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
| EP1968968A1 (en) | 2005-12-21 | 2008-09-17 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
| PT1928425E (pt) | 2006-05-12 | 2013-04-11 | Pharmathen Sa | Formulação farmacêutica contendo um inibidor de hmg-coa redutase e método para a preparação deste |
| WO2008092231A1 (en) * | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| EP2005941A3 (de) | 2007-06-01 | 2009-04-01 | Henkel AG & Co. KGaA | Zellverjüngende Zusammensetzungen |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2008157575A1 (en) | 2007-06-21 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| KR101629356B1 (ko) * | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| JP2011529932A (ja) | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| JP2012505160A (ja) * | 2008-10-06 | 2012-03-01 | カロラス セラピューティクス， インク． | 炎症を処置する方法 |
| US8569288B2 (en) | 2008-10-30 | 2013-10-29 | Circomed Llc | Thienotriazolodiazepine derivatives active on apo A |
| AU2010204106B2 (en) | 2009-01-08 | 2014-05-08 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| SG174252A1 (en) | 2009-03-06 | 2011-10-28 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| NZ755378A (en) | 2009-03-18 | 2022-07-29 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| EP2675445A1 (en) | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases |
| RU2640115C2 (ru) | 2011-11-01 | 2017-12-26 | Ресверлоджикс Корп. | Фармацевтические композиции замещенных хиназолинонов |
| RS56846B1 (sr) | 2012-10-15 | 2018-04-30 | Resverlogix Corp | Jedinjenja korisna za sintezu jedinjenja benzamida |
| ES2664050T3 (es) | 2012-10-15 | 2018-04-18 | Albemarle Corporation | Procesos para la síntesis de la 2-amino-4,6-dimetoxibenzamida y otros compuestos de benzamida |
| JP2016528276A (ja) | 2013-08-21 | 2016-09-15 | レスバーロジックス コーポレイション | プラーク退縮を促進するための組成物及び治療法 |
| WO2015025226A2 (en) | 2013-08-21 | 2015-02-26 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
| JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
-
2010
- 2010-04-21 KR KR1020197022099A patent/KR20190091564A/ko not_active Ceased
- 2010-04-21 LT LTEP10714825.6T patent/LT2421533T/lt unknown
- 2010-04-21 DK DK10714825.6T patent/DK2421533T3/en active
- 2010-04-21 EP EP18193312.8A patent/EP3431086B1/en not_active Not-in-force
- 2010-04-21 BR BRPI1014956A patent/BRPI1014956B8/pt not_active IP Right Cessation
- 2010-04-21 MX MX2016015962A patent/MX374414B/es unknown
- 2010-04-21 NZ NZ596117A patent/NZ596117A/en not_active IP Right Cessation
- 2010-04-21 AU AU2010239266A patent/AU2010239266B2/en not_active Ceased
- 2010-04-21 MX MX2011011048A patent/MX352614B/es active IP Right Grant
- 2010-04-21 HR HRP20182200TT patent/HRP20182200T1/hr unknown
- 2010-04-21 ES ES10714825T patent/ES2706651T3/es active Active
- 2010-04-21 CA CA2759241A patent/CA2759241C/en active Active
- 2010-04-21 TR TR2018/18390T patent/TR201818390T4/tr unknown
- 2010-04-21 ES ES18193312T patent/ES2821018T3/es active Active
- 2010-04-21 WO PCT/US2010/031870 patent/WO2010123975A1/en not_active Ceased
- 2010-04-21 KR KR1020187023996A patent/KR20180096823A/ko not_active Ceased
- 2010-04-21 JP JP2012507341A patent/JP5813626B2/ja not_active Expired - Fee Related
- 2010-04-21 PT PT10714825T patent/PT2421533T/pt unknown
- 2010-04-21 PL PL10714825T patent/PL2421533T3/pl unknown
- 2010-04-21 KR KR1020207027594A patent/KR102215167B1/ko not_active Expired - Fee Related
- 2010-04-21 EP EP10714825.6A patent/EP2421533B1/en active Active
- 2010-04-21 CN CN201710396072.6A patent/CN107252429B/zh not_active Expired - Fee Related
- 2010-04-21 SI SI201031807T patent/SI2421533T1/sl unknown
- 2010-04-21 CN CN201080027599.8A patent/CN102458405B/zh not_active Expired - Fee Related
- 2010-04-21 KR KR1020117027609A patent/KR101892987B1/ko not_active Expired - Fee Related
- 2010-04-21 US US13/265,060 patent/US9757368B2/en active Active
-
2011
- 2011-10-23 IL IL215799A patent/IL215799A/en active IP Right Grant
-
2014
- 2014-07-27 IL IL233822A patent/IL233822A/en active IP Right Grant
-
2017
- 2017-08-03 US US15/668,542 patent/US20170326143A1/en not_active Abandoned
- 2017-08-04 US US15/669,219 patent/US20170333419A1/en not_active Abandoned
-
2019
- 2019-06-14 US US16/441,793 patent/US20200129512A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524794A5 (https=) | ||
| ES2821018T3 (es) | Nuevos agentes antiinflamatorios | |
| CN1659144B (zh) | 喹啉和异喹啉衍生物、其制备方法以及作为炎症抑制剂的应用 | |
| JP2018507899A5 (https=) | ||
| JP2012520867A5 (https=) | ||
| JP3927175B2 (ja) | Ｎ−置換ヒドロキシピリミジノンカルボキサミド系ｈｉｖインテグラーゼ阻害薬 | |
| FI3788040T3 (fi) | Pyridatsinoneja parp7-inhibiittoreina | |
| JP2013538801A5 (https=) | ||
| JP2011504497A5 (https=) | ||
| JP2014521595A5 (https=) | ||
| JP2010517946A5 (https=) | ||
| JP2012502927A5 (https=) | ||
| HRP20110670T1 (hr) | Derivati 4-(2-amino-1-hidroksietil)fenola kao agonisti beta-2 adrenergičkog receptora | |
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| JP2018518522A5 (https=) | ||
| EA015358B1 (ru) | Хинолины и их терапевтическое применение | |
| JP2022511209A5 (https=) | ||
| CN101679311A (zh) | 喹唑啉化合物 | |
| Jain et al. | An explicative review on the progress of quinazoline scaffold as bioactive agents in the past decade | |
| CN110372666A (zh) | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 | |
| RU2016116435A (ru) | Производные фенил-дигидропиридина в качестве ингибиторов альдостеронсинтазы | |
| JPWO2023064133A5 (https=) | ||
| TW201202224A (en) | Optical pure quinazoline compounds | |
| HK1162148B (en) | Novel anti-inflammatory agents | |
| HK40003375A (en) | Novel anti-inflammatory agents |